Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Roxane Hillier, EURETINA 2022: Mechanisms of action in rhegmatogenous retinal detachment repair (Part 1)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 20th 2022

It was a pleasure to talk to Roxane Hillier (Newcastle Eye Centre, Newcastle, UK) on her EURETINA course on rhegmatogenous retinal detachment repair. In this interview, she discussed the treatment options for rhegmatogenous retinal detachment.

The instructional course entitled “Mechanisms of Action in Rhegmatogenous Retinal Detachment Repair” was conducted at EURETINA 2022, 1–4 September 2022 

  1. Could you give us a brief overview of the options for treating rhegmatogenous retinal detachment? (00:13)
  2. How does postoperative photoreceptor integrity vary with surgical technique used to repair primary rhegmatogenous retinal detachment? (01:54)

Disclosure: Roxane Hillier has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed as a highlight of EURETINA 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup